CompletedNot Applicable

Predicting Response to Capecitabine in Women With Metastatic Breast Cancer

France303 participantsStarted 2009-01

Plain-language summary

RATIONALE: Identifying genes that increase a person's susceptibility to side effects caused by capecitabine may help doctors plan better treatment. PURPOSE: This clinical trial is studying blood samples in predicting response to capecitabine in women with metastatic breast cancer.

Who can participate

Age range18 Years – 120 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

DISEASE CHARACTERISTICS: * Radiologically (by scintography) or histologically confirmed metastatic breast cancer * At least 1 measurable or evaluable target lesion * Receiving capecitabine as monotherapy or with targeted antiangiogenic therapies (e.g., bevacizumab or trastuzumab) * No uncontrolled brain metastases * Hormone receptor status not specified PATIENT CHARACTERISTICS: * Menopausal status not specified * Life expectancy ≥ 3 months * Fertile patients must use effective contraception * No chronic uncontrolled illness * No congestive heart failure * No peripheral venous disease * No severe uncontrolled infection * No hypoxemic respiratory failure * No prior primary cancer except for basal cell carcinoma of the skin * No psychologic disorder PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No capecitabine co-administered with chemotherapy

What they're measuring

Capecitabine-related toxicity (i.e., hematological, diarrhea, and hand-foot syndrome) recorded during the first and second courses

Timeframe: 3 months

Trial details

NCT IDNCT00953537

SponsorCentre Antoine Lacassagne

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2011-01

View on ClinicalTrials.gov More Breast Cancer trials